Category: Disclosures

[Disclosure] Samsung Biologics (207940) – (Correction) Major Management Matters Related to Investment Decisions / 2024-12-19

December 19, 2024August 7, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has issued a correction disclosure regarding its Letter of Intent (LOI) for a biopharmaceutical contract manufacturing agreement with a Europe-based pharmaceutical company, extending the disclosure postponement deadline for the counterparty’s identity from December 31, 2024, to December 31, 2030, upon the customer’s request. 📊…

Disclosures, Bio & Healthcare

[Disclosure] Samsung Biologics (207940) – (Correction) Major Management Matters Related to Investment Decisions / 2024-12-19

December 19, 2024August 7, 2026 K-STOCK Editor

Disclosures, Bio & Healthcare

[Disclosure] LEENO Industrial (058470) – Decision on Cash/In-Kind Dividend / 2024-12-19

December 19, 2024August 4, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary LEENO Industrial has resolved on a year-end cash dividend of KRW 3,000 per common share for FY2024, totaling approximately KRW 45.54 billion. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of AGM Approval and Corrected Dividend Yield Disclosures The…

Semiconductors, Disclosures

[Disclosure] Hanwha Systems (272210) – Sales and Supply Contract / 2024-12-18

December 18, 2024August 11, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Hanwha Systems has signed a contract worth approximately KRW 112.3B with the Defense Acquisition Program Administration for Performance-Based Logistics (PBL) for K2 Tank Fire Control Systems and 3 other items. 📊 [Key Disclosure Details & Financial Metrics] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Contract Performance…

Disclosures, Defense

[Disclosure] Samsung Biologics (207940) – (Correction) Single Sales and Supply Contract / 2024-12-18

December 18, 2024August 7, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has issued a correction disclosure regarding its pharmaceutical contract manufacturing agreement with a US-based pharmaceutical company, extending the contract end date and disclosure postponement deadline from December 31, 2024, to December 31, 2026, upon the customer’s request. 📊 [Key Disclosure Details & Financial Figures]…

Disclosures, Bio & Healthcare

[Disclosure] Samsung Biologics (207940) – (Correction) New Facility Investment / 2024-12-18

December 18, 2024August 7, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has issued a correction disclosure regarding its new facility investment in Plant 5 at Songdo 2nd Bio Campus, updating the total investment amount from KRW 1.9801T to KRW 2.0098T. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Monitoring…

Disclosures, Bio & Healthcare

[Disclosure] Hanwha Aerospace (012450) – Supply Contract / 2024-12-18

December 18, 2024August 10, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Hanwha Aerospace has disclosed a supply contract with the Defense Acquisition Program Administration (DAPA) valued at approximately KRW 709.3B for the 4th mass production batch of K21 Infantry Fighting Vehicles and 21 other items. 📊 [Key Disclosure Contents & Major Financial Figures] 1. Contract Details and…

Disclosures, Defense

[Disclosure] Celltrion (068270) – Approval of US FDA Marketing Authorization for Steqeyma (CT-P43, Stelara Biosimilar) / 2024-12-18

December 18, 2024August 6, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion received final marketing authorization from the US Food and Drug Administration (FDA) for Steqeyma (CT-P43), a Stelara biosimilar, for key indications including plaque psoriasis and Crohn’s disease across the United States. 📊 Key Disclosure Content & Financial Highlights 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌…

Disclosures, Bio & Healthcare

[Disclosure] Celltrion (068270) – Advance Notice of Equity Futures & Options Market Measures (Planned Market Measures Due to Stock Dividend) / 2024-12-18

December 18, 2024August 6, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary The Korea Exchange (KRX) issued an advance notice regarding scheduled derivatives market measures—including adjustments to base prices, contract multipliers, and strike prices—for Celltrion equity futures and options, effective December 27, 2024 (ex-dividend date), following Celltrion’s stock dividend decision. 📊 Key Disclosure Content & Financial Highlights 📝…

Disclosures, Bio & Healthcare

[Disclosure] Daeduck Electronics (353200) – Advance Notice of Earnings Release (Information Disclosure) / 2024-10-17

December 17, 2024August 4, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Daeduck Electronics has announced in advance that it plans to disclose its provisional Q3 2024 financial results on October 31, 2024. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Earnings Release Disclosure and Final Confirmed Figures Through this…

Semiconductors, Disclosures